Skip to main content
Premium Trial:

Request an Annual Quote

Med BioGene Adopts Shareholder Rights Plan

NEW YORK (GenomeWeb News) – Canadian diagnostic developer Med BioGene announced the adoption of a shareholder rights plan.

Med BioGene said that the purpose of the rights plan is to provide sufficient time to its board and shareholders to assess any unsolicited bids to take over the company, and to allow the board to consider "value-enhancing" alternatives and entertain competing bids.

The rights plan is subject to ratification by shareholders at the company's annual meeting, to be held on Feb. 12.

Med BioGene noted that it is not aware of, nor is it seeking ratification of the rights plan in anticipation of, any pending or threatened takeover bid.

Shares of the Vancouver-based company are traded on Canada's TSX Venture Exchange. Last month, Med BioGene filed for an initial public offering in the US, and said that it would use the proceeds from the IPO to validate its first diagnostic test, called LungExpress Dx, on a real-time, quantitative reverse transcriptase PCR platform.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.